Physician profile
Mackenzie Keys
NPI 1730671405
$4,149.34
in general payments reported to CMS, 2019-2025
18 companies · $1,158 in 2025
The $1,158 reported for 2025 was more than what 83% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $320 · 2022: $769 · 2023: $1,338 · 2024: $564 · 2025: $1,158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,998 · Education: $62.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,997.84 |
| Education | $62.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,773.62 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $443.79 | 2021-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Lundbeck LLC | $378.49 | 2022-2025 | Abilify Maintena, Rexulti |
| Alkermes, INC. | $275.34 | 2021-2023 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $257.94 | 2024-2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $215.78 | 2022-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $169.66 | 2022-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $135.43 | 2022-2025 | Caplyta |
| Indivior INC. | $124.95 | 2022-2024 | Perseris |
| Teva Pharmaceuticals USA, INC. | $89.34 | 2022-2025 | Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $68.33 | 2025 | |
| Vanda Pharmaceuticals INC. | $65.04 | 2024-2025 | Hetlioz, Fanapt |
| Supernus Pharmaceuticals, INC. | $46.07 | 2023-2025 | Qelbree, Qelbree |
| Corium, LLC | $36.34 | 2023-2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $21.55 | 2025 | Jornay Pm |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $19.71 | 2021 | |
| Luye Pharma (USA) Ltd. | $14.40 | 2025 | Erzofri Extended-Release |
| Eisai INC. | $13.56 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mackenzie Keys listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.